Literature DB >> 2808258

Effect of anxiety on cognition, behavior, and stimulant response in ADHD.

S R Pliszka.   

Abstract

The effect of the comorbidity of overanxious disorder (ANX) in attention deficit hyperactivity disorder (ADHD) on laboratory measures of behavior, cognition, and stimulant response was examined. Seventy-nine children who met DSM-III-R criteria for ADHD were tested further for an oppositional defiant disorder (ODD), conduct disorder (CD), or ANX. Subjects with comorbid ANX showed less impulsiveness on a laboratory measure of behavior and had longer, sluggish reaction times on the Memory Scanning Test than those without ANX. ADHD subjects with comorbid ANX were less frequently diagnosed as CD. Forty-three of the subjects completed a double-blind trial of methylphenidate; subjects with comorbid anxiety had a significantly poorer response to the stimulant than those without anxiety, while the comorbidity of ODD or CD did not affect stimulant response. The results suggest that ADHD with comorbid ANX may represent children with primary anxiety who develop secondary inattentiveness, or they may represent a different subtype of ADHD, perhaps similar to the condition of attention deficit disorder without hyperactivity under DSM-III.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2808258     DOI: 10.1097/00004583-198911000-00012

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  53 in total

Review 1.  Non-stimulant treatments for ADHD.

Authors:  J Biederman; T Spencer
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

2.  Ferritin and hyperactivity ratings in attention deficit hyperactivity disorder.

Authors:  Pinar Oner; Ozgur Oner; Fatih M Azik; Esra Cop; Kerim M Munir
Journal:  Pediatr Int       Date:  2012-07-19       Impact factor: 1.524

3.  Anxiety modulates the relation between attention-deficit/hyperactivity disorder severity and working memory-related brain activity.

Authors:  Dennis van der Meer; Pieter J Hoekstra; Daan van Rooij; Anderson M Winkler; Hanneke van Ewijk; Dirk J Heslenfeld; Jaap Oosterlaan; Stephen V Faraone; Barbara Franke; Jan K Buitelaar; Catharina A Hartman
Journal:  World J Biol Psychiatry       Date:  2017-03-01       Impact factor: 4.132

4.  Evidence of poor planning in children with attention deficits.

Authors:  Timothy C Papadopoulos; Georgia Panayiotou; George Spanoudis; Demetrios Natsopoulos
Journal:  J Abnorm Child Psychol       Date:  2005-10

5.  Managing ADHD in children, adolescents, and adults with comorbid anxiety in primary care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

6.  Brief report: response to methylphenidate in two children with Williams syndrome.

Authors:  T J Power; N J Blum; S M Jones; P E Kaplan
Journal:  J Autism Dev Disord       Date:  1997-02

7.  Treatment of attention deficit hyperactivity disorder in children. Predictors of treatment outcome.

Authors:  Saskia van der Oord; P J M Prins; J Oosterlaan; P M G Emmelkamp
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

8.  European clinical guidelines for hyperkinetic disorder -- first upgrade.

Authors:  Eric Taylor; Manfred Döpfner; Joseph Sergeant; Philip Asherson; Tobias Banaschewski; Jan Buitelaar; David Coghill; Marina Danckaerts; Aribert Rothenberger; Edmund Sonuga-Barke; Hans-Christoph Steinhausen; Alessandro Zuddas
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

Review 9.  Non-stimulant medications in the treatment of ADHD.

Authors:  Tobias Banaschewski; Veit Roessner; Ralf W Dittmann; Paramala Janardhanan Santosh; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

Review 10.  Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants.

Authors:  Jan Buitelaar; Rossella Medori
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-10-13       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.